[brokerage Focus] Haitong Int'l maintains a 'outperform the market' rating for JD Health (06618), expecting the strength of the self-operated business in the second half of the year to catalyze performance.

Jingtou Finance News | Haitong International's research report pointed out that JD Health (06618) achieved revenue of 13.3 billion yuan in the third quarter of 2024, an increase of 14.8%; operating profit of 0.55 billion yuan, an increase of 216.0%; adjusted operating profit of 0.86 billion yuan, an increase of 15.7%; net income of 0.93 billion yuan, an increase of 212.2%; adjusted net income of 1.34 billion yuan, an increase of 40.6%. Corresponding net margin of 7.0% (+4.4pct), adjusted net margin of 10.0% (+1.8pct).

Jinwu Financial NewsNov 25 20:05 ET

The three major Hong Kong stock indexes continued to show a volatile trend, with the lithium battery and golden industrial concept sectors performing prominently.

① Why have international gold prices strengthened? ② What news has stimulated the strength of consumer electronics stocks? ③ Has the short sell ratio in the Hong Kong stock market shown a decline?

cls.cnNov 19 03:34 ET

China Merchants Securities: The "AI + Healthcare" TOC application is beneficial to the public, and leading enterprises are expected to benefit first.

The introduction of AI is expected to improve data accuracy and continuity (asia vets wearable devices for continuous data collection, in conjunction with patient hospital medical records), provide professional personalized health services (AI doctors/nurses), and create more possibilities (brain-computer interfaces offer assistance in movement and neurological rehabilitation, improving the quality of life for people with disabilities, etc.).

Zhitong FinanceNov 19 00:44 ET

Nomura Adjusts JD Health International's Price Target to HK$31 From HK$25, Keeps at Buy

MT NewswiresNov 18 02:21 ET · Ratings

jd health (06618.HK): Revenue in the third quarter reached 13.302 billion yuan, with both revenue and profit soaring.

Healthcare JD.com (06618.HK) announced on November 14th that in the third quarter of 2024, revenue reached RMB 13.302 billion, a year-on-year increase of 14.8%; operating profit reached RMB 0.552 billion, a year-on-year increase of 216.0%; net profit reached RMB 0.932 billion, a year-on-year increase of 212.2%; non-IFRS net profit reached RMB 1.336 billion, a year-on-year increase of 40.6%. During the reporting period, JD Health continued to deepen its cooperation with pharmaceutical companies, and several new drugs were successively launched at JD's flagship pharmacy, including products haisco pharmaceutical group.

Gelonghui FinanceNov 14 04:10 ET

Express News | JD Health International - Qtrly Profit RMB932.2 Mln

ReutersNov 14 04:01 ET